A multicenter phase 1/2 study to evaluate the combination of pegzilarginase and pembrolizumab for the treatment of patients with small cell lung cancer

Trial Profile

A multicenter phase 1/2 study to evaluate the combination of pegzilarginase and pembrolizumab for the treatment of patients with small cell lung cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Pegzilarginase (Primary) ; Pembrolizumab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 New trial record
    • 16 Oct 2017 According to an Aeglea BioTherapeutics media release, this trial is expected to begin enrollment in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top